Future Oncology 10th anniversary SFI celebrates the past, present and future in cancer

October 08, 2015

Future Oncology is celebrating its tenth anniversary by publishing a Special Focus issue documenting the past, present and future of several cancers. Such is the extent of the progress seen in all fields of oncology since the journal's debut in 2005, that authors were invited to document these advancements in the issue, with speculation as to how further progress will be made in the coming years. The journal is published by Future Medicine, an imprint of Future Science Group.

"This issue marks the 10th Anniversary of Future Oncology, a dynamic cancer journal highlighting the progress of various areas in oncology," commented Simon Lo, a member of the Future Oncology Editorial Board and contributor to the issue. "The journal is at the forefront of reporting and addressing the most important clinical and scientific issues as well as research findings in oncology."

The issue includes several review articles from renowned authors, covering areas such as: immunotherapy for non-small cell lung cancer, the development of stereotactic body radiotherapy, personalized therapy for colorectal cancer and fertility preservation in cancer patients. Editorial articles include coverage of image-guided brachytherapy in cervical cancer, metastatic gastric cancer and the role of chemotherapy in prostate cancer.

"We are excited to be publishing this Special Focus issue of Future Oncology, which includes a number of comprehensive review articles from diverse oncology specialties," commented Nick Ward, Commissioning Editor of Future Oncology. "The issue aims to highlight and celebrate the vast progress made in several research areas and provide a future outlook on how the field will evolve."
To read the full issue, please click here

Additional articles and cancer content can be found on Oncology Central, Future Science Group's free eCommunity for oncology professionals. The membership-based portal offers free access to breaking oncology news and peer-reviewed journal articles, with content selected by fellow clinicians.

About Future Oncology

Future Oncology is a MEDLINE-indexed journal, with an impact factor of 2.477. The journal covers the latest scientific and clinical issues, together with the economic and policy issues of relevance to oncologists. The journal delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites includes Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

http://www.future-science-group.com | http://www.futuremedicine.com | http://www.future-science.com

Future Science Group

Related Cervical Cancer Articles from Brightsurf:

HPV strains may impact cervical cancer prognosis
An analysis of cervical cancers in Ugandan women has uncovered significant genomic differences between tumours caused by different strains of human papillomavirus (HPV), signifying HPV type may impact cervical cancer characteristics and prognosis.

American Cancer Society updates guideline for cervical cancer screening
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.

Disasters can affect cervical cancer screening for years
Screening is important for the early detection of cervical cancer, but rates were significantly affected, in some areas for years, following a devastating earthquake and tsunami in Japan.

Cervical cancer elimination possible within two decades in the US
At current levels of screening and HPV vaccination, cervical cancer incidence in the US is projected to fall below the threshold of elimination by 2038-2046.

Cervical cancer screening saves lives
Three-year interval in screening for cervical cancer is as effective as annual checkups, study finds.

Cervical cancer could be eliminated within a century
Cervical cancer could be eliminated worldwide as a public health issue within the next century.

25 years of learning to combat cervical cancer
A recent paper from the lab of Professor Sudhir Krishna at the National Centre for Biological Sciences, Bangalore, reviews the progress made in cervical cancer research over the past 25 years.

Cervical cancer screening numbers drop off in women 45-65
Virtually all cervical cancers are caused by HPV, and much of the attention in recent years has focused on preventing infections in younger women through HPV vaccination.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cost-effectiveness analysis of 12 cervical cancer screenings
This cost-effectiveness analysis incorporates women's preferences and estimates quality of life and economic outcomes for 12 cervical cancer screening strategies.

Read More: Cervical Cancer News and Cervical Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.